|
Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. |
|
|
Consulting or Advisory Role - Eisai; Forty Seven; Horizant; Kyowa Hakko Kirin; Millennium; Portola Pharmaceuticals; Seagen |
Research Funding - Eisai; Forty Seven; Innate Pharma; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Merck; Millennium; miRagen; Neumedicines; Seagen; Soligenix; TetraLogic Pharmaceuticals |
|
|
Consulting or Advisory Role - Takeda |
Research Funding - Takeda |
|
|
Consulting or Advisory Role - Takeda |
|
|
Consulting or Advisory Role - Celgene; Forty Seven; HUYA Bioscience International; Infinity Pharmaceuticals; Kyowa Hakko Kirin; Millennium; Seagen |
Research Funding - ADC Therapeutics; Aileron Therapeutics; Celgene; Forty Seven; Infinity Pharmaceuticals; Kyowa Hakko Kirin; Seagen; Spectrum Pharmaceuticals; Takeda |
|
|
Consulting or Advisory Role - Millennium; Seagen |
Research Funding - Millennium; Seagen |
|
|
Consulting or Advisory Role - 4SC; Millennium; Therakos |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
Maria Corinna Palanca Wessels |
|
Stock and Other Ownership Interests - Seagen |
|
|
|
|
|
|
|
|
|
Stock and Other Ownership Interests - Takeda |
|
|
|
Stock and Other Ownership Interests - Takeda |
|
|
|
Stock and Other Ownership Interests - Takeda |
|
|
|
|
|
|
|
|
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Takeda |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Takeda |
Research Funding - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Takeda |